A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Trial Details

NCT ID
NCT06678659
Phase
PHASE1 / PHASE2
Sponsor
Recursion Pharmaceuticals Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • REC-1245
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • West Valley City, Utah, United States|40.69161,-112.00105
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
  • Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a …
  • Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performa…
  • Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomograph…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →